User Fee Goals For Recently Announced NDA/BLA Submissions
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
User Fee Goals For Recently Announced NDA/BLA Submissions
You may also be interested in...
Oral Zemplar NDA Submission, Hectorol Launch Heat Up Pre-Dialysis Market
Expanding the use of vitamin D analogs to earlier-stage chronic kidney disease patients will be a frequent topic of promotional activity in coming months, as Abbott prepares the market for its recently filed oral formulation of Zemplar and Bone Care International begins launch of a new version of Hectorol.
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product